Octavian Therapeutics
PrivateLast Round
Early Funding
Mar 1, 2025
Est. Valuation
$72.57M
Total Funding Raised
$22.36M
Company Overview
Octavian Therapeutics operates in Healthcare & Life Sciences and is based in Oxford. Its latest recorded funding round was a Series A round in June 2018.
Octavian Therapeutics is a biopharmaceutical company focused on developing innovative prescription medicines targeting the endocannabinoid system to treat chronic neuropathic pain and other debilitating conditions.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Octavian Therapeutics Comparables
Compare Octavian Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| MIRA Pharmaceuticals, Inc. | 78% | |
| BRC Therapeutics | 78% | |
| Centrexion Therapeutics | 78% |
For institutional investors. Book with your work email.
Octavian Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Early Funding | Mar 1, 2025 | ||||
| IPO | May 21, 2021 | ||||
| Series A | Jun 28, 2018 | ||||
| Seed | Mar 17, 2017 |
For institutional investors. Book with your work email.
Octavian Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Casa Verde Capital | Series A |
| Kingsley Capital Partners | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 21, 2021
$23.25M raised in IPO round.
- Jun 28, 2018
$10M round led by Casa Verde Capital.
For institutional investors. Book with your work email.
Octavian Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Octavian Therapeutics's valuation, stock price, and market status.
Is Octavian Therapeutics a public or private company?
Octavian Therapeutics is a private company.
What is the current stock price of Octavian Therapeutics?
Octavian Therapeutics is a private company, so its shares have no public market price. Caplight tracks Octavian Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Octavian Therapeutics worth (valuation)?
Octavian Therapeutics's valuation is estimated at $72.6M based on funding round data.
Can I buy Octavian Therapeutics stock?
Octavian Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Octavian Therapeutics's last funding round?
Octavian Therapeutics's most recent funding round was Early Funding on March 1, 2025.
Who are the main investors in Octavian Therapeutics?
Key investors in Octavian Therapeutics include Kingsley Capital Partners.
Will Octavian Therapeutics IPO soon?
No public IPO plans have been announced for Octavian Therapeutics.
How can I track Octavian Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Octavian Therapeutics's shares on secondary markets.